Investing in the best psychedelic stocks today could be like getting in on the ground floor of the medical marijuana industry.

The governor of Wisconsin is thinking about adding marijuana legalization to his 2021 budget proposal as a means to boost tax revenue amid the coronavirus pandemic. ​​​​​​​

A panel of Minnesota lawmakers is backing the decriminalization of marijuana and expunging past cannabis records as a way to help “dismantle systemic racism” in the state.

NEW YORK, Dec. 21, 2020 /PRNewswire/ — Investments continued flowing into the psychedelic medicine sector this year and will likely continue in 2021 as mental illness cases rise across the globe.

While many 2020 memories will be gladly left behind, that’s not necessarily the case for psychedelics.

After a great year in 2020, psychedelic drug stocks are poised for an even better year in 2021.

2020 was a very good year for the psychedelic drug industry. Psychedelic Stock Watch has compiled our own Report Card on industry performance.

U.S. cannabis sales increased 67 percent in 2020 to $17.9 billion, which is $7.2 billion more than last year’s total.

“May revolutionize mental health care” – Fortune Dear %%First Name|Friend%%, One of the greatest shake-ups of the healthcare industry is underway.  Top medical researchers have begun to focus on a unique, controversial, and potentially highly effective treatment for some of the world’s most complex and costly mental health conditions including…

Eleusis acquires a ketamine therapy provider and announces a new R&D program.